In China, ovarian cancer patients' sensitivity to platinum-based chemotherapy is predicted by HRD detection.

Published Date: 26 Apr 2023

A biomarker known as homologous recombination deficiency (HRD) indicates whether breast cancer will be treated with platinum-based chemotherapy in the first instance or with PARP inhibitors for the treatment of ovarian cancer. However, there is little documented research.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

2.

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

3.

AI catches one-third of interval breast cancers missed at screening

4.

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

5.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot